Nanjing Vazyme Biotech Co Ltd Working Capital to Net Assets Ratio
Nanjing Vazyme Biotech Co Ltd working capital to net assets ratio. Nanjing Vazyme Biotech Co Ltd (688105) has a Working Capital to Net Assets ratio of 70.2% as of June 2026. Working capital of CN¥2.53 Billion (current assets of CN¥3.38 Billion minus current liabilities of CN¥845.66 Million) is measured against net assets of CN¥3.60 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. Check 688105 goodwill-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Working Capital to Net Assets Ratio of Nanjing Vazyme Biotech Co Ltd (2017–2025)
Working capital to net assets ratio of Nanjing Vazyme Biotech Co Ltd from 2017 to 2025. This chart shows how Nanjing Vazyme Biotech Co Ltd's Working Capital to Net Assets ratio has evolved across 9 annual periods from 2017 to 2025. As of June 2026, the ratio stands at 70.2%, reflecting working capital of CN¥2.53 Billion against net assets of CN¥3.60 Billion CNY. See operational self-sufficiency of Nanjing Vazyme Biotech Co Ltd to measure how many days the company can operate on defensive assets alone.
Nanjing Vazyme Biotech Co Ltd Working Capital to Net Assets Ratio by Year (2017–2025)
Nanjing Vazyme Biotech Co Ltd working capital to net assets ratio by year from 2017 to 2025. The table below presents the year-by-year Working Capital to Net Assets ratio for Nanjing Vazyme Biotech Co Ltd from 2017 to 2025, covering 9 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see 688105 asset base.
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 70.3% | CN¥2.67 Billion | CN¥3.79 Billion | CN¥3.71 Billion | CN¥1.04 Billion | ▲ +2.7 pp |
| 2024 | 67.7% | CN¥2.67 Billion | CN¥3.94 Billion | CN¥3.57 Billion | CN¥903.33 Million | ▲ +0.4 pp |
| 2023 | 67.3% | CN¥2.71 Billion | CN¥4.03 Billion | CN¥4.23 Billion | CN¥1.52 Billion | ▼ -6.7 pp |
| 2022 | 74.0% | CN¥3.41 Billion | CN¥4.61 Billion | CN¥4.57 Billion | CN¥1.15 Billion | ▼ -14.8 pp |
| 2021 | 88.8% | CN¥3.66 Billion | CN¥4.13 Billion | CN¥4.05 Billion | CN¥387.26 Million | ▲ +2.0 pp |
| 2020 | 86.8% | CN¥1.16 Billion | CN¥1.33 Billion | CN¥1.40 Billion | CN¥239.23 Million | ▲ +24.8 pp |
| 2019 | 62.0% | CN¥124.09 Million | CN¥200.02 Million | CN¥232.59 Million | CN¥108.49 Million | ▲ +4.5 pp |
| 2018 | 57.6% | CN¥95.61 Million | CN¥166.08 Million | CN¥175.64 Million | CN¥80.02 Million | ▼ -14.2 pp |
| 2017 | 71.7% | CN¥108.19 Million | CN¥150.82 Million | CN¥144.21 Million | CN¥36.02 Million | — |